CRI Logo
  • About
    • Impact
    • History
    • Team
    • Careers
    • Blog
    • Media Room
  • What is Immunotherapy?
    • Immunotherapy Basics
    • Treatment Types
    • Cancer Types
    • Side Effects
  • Patient Support
    • Patient Resources
    • Clinical Trials
    • Immunotherapy Stories
    • Connect with ImmunoAdvocates
  • Grants & Research Programs
    • Apply for Grants
    • Research Programs
    • Clinical Programs
    • Data Programs
    • CRI Funded Scientists
  • Get Involved
    • Ways to give
    • Fundraise
    • Events
    • Partnership
    • Contact
Donate

Immune to Cancer: The CRI Blog

  • AACR17 Update: Checkpoint Immunotherapy Clinical Trials in Melanoma and Lung Cancer

    In-depth analysis of long-term clinical trial data provides important insights for doctors treating…

    April 6, 2017| Arthur N. Brodsky, PhD
  • Pembrolizumab (Keytruda®) Approved as First-Line Option for Lung Cancer

    Anti-PD-1 checkpoint antibody is the only immunotherapy approved for first-line treatment for lung cancer patients.

    October 25, 2016| Arthur N. Brodsky, PhD
  • FDA Approves Another Immunotherapy Option for Patients with Advanced Lung Cancer

    Anti-PD-L1 atezolizumab is the second PD-1 pathway drug approved for lung cancer this month.

    October 18, 2016| Arthur N. Brodsky, PhD
  • Checkpoint Inhibitors Benefit Lung Cancer Patients in Clinical Trials

    Patients with metastatic non-small cell lung cancer could soon have a new first-line immunotherapy treatment option.

    October 14, 2016| Arthur N. Brodsky, PhD
  • ASCO 2016 Update: Advances in Immunotherapy for Lung and Blood Cancers

    Combination checkpoints, improved CAR T cells show promise.

    June 5, 2016| Arthur N. Brodsky, PhD
  • FDA Approves Expanded Use of Nivolumab for Lung Cancer

    Nivolumab, a PD-1 immunotherapy, is now approved as second-line therapy for the most common type of lung…

    October 9, 2015| Matthew Tontonoz
  • FDA Approves PD-1 Immunotherapy for Most Common Type of Lung Cancer

    Patients with non-small cell lung cancer may now receive a PD-1 immunotherapy as second-line treatment after chemotherapy.

    October 2, 2015| Matthew Tontonoz
  • What Patients Need to Know About Lung Cancer Immunotherapy

    Join us on August 21 as Julie Brahmer, MD, discusses the latest research and current treatments for…

    August 14, 2015| Michelle Liew
  • New Clinical Trials to Offer Immunotherapy as Frontline Treatment for Lung Cancer

    Patients with lung cancer will soon be able to receive immunotherapy as first-line treatment on an experimental…

    July 7, 2015| Matthew Tontonoz
Previous Page
1 2 3 4
Next Page

Cancer Research Institute
29 Broadway, Floor 4

New York, NY  10006-3111

Facebook Icon
X icon
YouTube icon
LinkedIn icon
Instagram icon
Threads icon
  • About
    • Impact
    • History
    • Team
    • Careers
    • Blog
    • Media Room
  • What is Immunotherapy?
    • Immunotherapy Basics
    • Treatment Type
    • Cancer Type
    • Side Effects
  • Patient Support
    • Patient Resources
    • Clinical Trials
    • Immunotherapy Stories
    • Connect with ImmunoAdvocates
  • Grants & Research Programs
    • Apply for Grants
    • Research Programs
    • Clinical Programs
    • Data Programs
    • CRI Funded Scientists
  • Get Involved
    • Donate
    • Ways to give
    • Fundraise
    • Events
    • Partnership
    • Contact

Uniting for a World Immune to Cancer

  • Accessibility Statement
  • Privacy Policy
  • Terms & Conditions
  • Site Map

*Immunotherapy results may vary from patient to patient.

©2025, Cancer Research Institute